- Home
- VLGEA vs ANAB Comparison
VLGEA vs ANAB Comparison
Compare VLGEA & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VLGEA
- ANAB
- Stock Information
- Founded
- VLGEA 1937
- ANAB 2005
- Country
- VLGEA United States
- ANAB United States
- Employees
- VLGEA N/A
- ANAB N/A
- Industry
- VLGEA Food Chains
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- VLGEA Consumer Staples
- ANAB Health Care
- Exchange
- VLGEA Nasdaq
- ANAB Nasdaq
- Market Cap
- VLGEA 532.5M
- ANAB 591.4M
- IPO Year
- VLGEA N/A
- ANAB 2017
- Fundamental
- Price
- VLGEA $37.98
- ANAB $23.70
- Analyst Decision
- VLGEA
- ANAB Buy
- Analyst Count
- VLGEA 0
- ANAB 10
- Target Price
- VLGEA N/A
- ANAB $44.25
- AVG Volume (30 Days)
- VLGEA 35.7K
- ANAB 682.7K
- Earning Date
- VLGEA 06-03-2025
- ANAB 08-04-2025
- Dividend Yield
- VLGEA 2.65%
- ANAB N/A
- EPS Growth
- VLGEA 12.55
- ANAB N/A
- EPS
- VLGEA 3.80
- ANAB N/A
- Revenue
- VLGEA $2,299,253,000.00
- ANAB $111,872,000.00
- Revenue This Year
- VLGEA N/A
- ANAB N/A
- Revenue Next Year
- VLGEA N/A
- ANAB $24.39
- P/E Ratio
- VLGEA $9.90
- ANAB N/A
- Revenue Growth
- VLGEA 3.94
- ANAB 387.20
- 52 Week Low
- VLGEA $24.57
- ANAB $12.21
- 52 Week High
- VLGEA $40.15
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- VLGEA 56.02
- ANAB 62.40
- Support Level
- VLGEA $37.25
- ANAB $19.04
- Resistance Level
- VLGEA $40.15
- ANAB $24.68
- Average True Range (ATR)
- VLGEA 1.08
- ANAB 1.74
- MACD
- VLGEA 0.00
- ANAB 0.14
- Stochastic Oscillator
- VLGEA 51.67
- ANAB 82.62
About VLGEA Village Super Market Inc.
Village Super Market Inc operates a chain of ShopRite supermarkets, a few of which are in northern New Jersey, southern New Jersey, Maryland, and in northeastern Pennsylvania. The company is a member of Wakefern Food Corporation (Wakefern), a retailer-owned food cooperative and owner of the ShopRite name. It consists of one operating segment, the retail sale of food and nonfood products.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).